2026-04-17T01:06:31Zhttps://recercat.cat/oai/requestoai:recercat.cat:20.500.12328/28372025-05-20T00:04:11Zcom_2072_67741col_2072_484352
2025-05-20T00:04:11Z
urn:hdl:20.500.12328/2837
Trichodynia and telogen effluvium in COVID-19 patients: results of an international expert opinion survey on diagnosis and management
Starace, Michela
Iorizzo, Matilde
Sechi, Andrea
Alessandrini, Aurora Maria
Carpanese, Miriam
Bruni, Francesca
Vara, Giulio
Apalla, Zoe
Asz-Sigall, Daniel
Barruscotti, Stefania
Camacho, Francisco
Doche, Isabella
Duque Estrada, Bruna
Dhurat, Rachita
Gavazzoni, Maria Fernanda
Grimalt Santacana, Ramon
Harries, Matthew
Ioannidis, Dimitrios
McMichael, Amy
Fernandes Melo, Daniel
Oliveira, Rui
Ovcharenko, Yuliya
Pirmez, Rodrigo
Ramot, Yuval
Rudnicka, Lidia
Shapiro, Jerry
Silyuk, Tatiana
Sinclair, Rodney
Tosti, Antonella
Vano-Galvan, Sergio
Piraccini, Bianca Maria
COVID-19 (Malaltia)
Caiguda de cabell
Pèrdua de cabells
Vessament de cabell
Alodinia cuir cabellut
Efluvi telogen
Tricodínia
COVID-19
Perdida de cabello
Caída del cabello
Alodinia del cuero cabelludo
Efluvio telógeno
Tricodinia
COVID-19
Hair loss
Hair shedding
Scalp allodynia
Telogen effluvium
Trichodynia
Background: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. Objective: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. Methods: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. Limitations: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.
2025-05-20T00:04:11Z
2025-05-20T00:04:11Z
2021
info:eu-repo/semantics/article
Starace, Michela; Iorizzo, Matilde; Sechi, Andrea [et al.]. Trichodynia and telogen effluvium in COVID-19 patients: results of an international expert opinion survey on diagnosis and management. JAAD International, 2021, 5, p. 11-18. Disponible en: <https://www.sciencedirect.com/science/article/pii/S2666328721000560?via%3Dihub>. Fecha de acceso: 4 oct. 2021. DOI: 10.1016/j.jdin.2021.07.006
2666-3287
http://hdl.handle.net/20.500.12328/2837
https://dx.doi.org/10.1016/j.jdin.2021.07.006
eng
JAAD International
5;
https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jdin.2021.07.006
Elsevier